Kolesterolsænkende behandling med PCSK9-inhibitorer

Keyphrases

• Adverse Events Profile 50%
• Cardiovascular Disease 50%
• Cardiovascular Endpoints 50%
• Cardiovascular Outcomes 50%
• Cardiovascular Risk Reduction 50%
• Dietary Intervention 50%
• Evolocumab 100%
• Ezetimibe 50%
• High-risk Individuals 50%
• Lipid-lowering Drugs 50%
• Low-density Lipoprotein 50%
• Monoclonal Antibody 50%
• PCSK9 Inhibitors 100%
• Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) 50%
• Statins 50%
• Ultra-high Risk 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 50%
• Antilipemic Agent 50%
• Cardiovascular Disease 50%
• Ezetimibe 50%
• Low Density Lipoprotein 50%
• Monoclonal Antibody 50%
• Proprotein Convertase 9 50%
• Statin (Protein) 50%